Literature DB >> 18029454

Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state.

Sridevi Devaraj1, Mohan R Dasu, Jason Rockwood, William Winter, Steven C Griffen, Ishwarlal Jialal.   

Abstract

CONTEXT: Type 1 diabetes (T1DM) is associated with increased cardiovascular mortality. It is a pro-inflammatory state as evidenced by increased circulating biomarkers and monocyte activity. The toll-like receptors (TLRs) are pattern recognition receptors, expressed abundantly on monocytes. TLR2 and TLR4 are important in atherosclerosis. However, there is a paucity of data examining TLR2 and TLR4 expression in T1DM and examining its contribution to the proinflammatory state.
OBJECTIVE: Thus, we examined TLR2 and TLR4 expression in monocytes from T1DM patients compared with controls (n = 31 per group).
SETTING: The study was performed at the University of California Davis Medical Center. PATIENTS: Healthy controls (n = 31) and T1DM patients (n = 31) were included in the study.
RESULTS: TLR2 and TLR4 surface expression and mRNA were significantly increased in T1DM monocytes compared with controls. Downstream targets of TLR, nuclear factor kappaB, myeloid differentiation factor 88, Trif, and phosphorylated IL-1 receptor-associated kinase were significantly up-regulated in T1DM. Finally, the release of IL-1beta and TNF-alpha was significantly increased in monocytes from T1DM compared with controls and correlated with TLR2 and TLR4 expression (P < 0.005). In addition, TLR2 and TLR4 expression was significantly correlated to glycosylated hemoglobin, carboxymethyllysine, and nuclear factor kappaB (P < 0.02).
CONCLUSION: Thus, we make the novel observation that TLR2 and TLR4 expression and signaling are increased in T1DM and contribute to the proinflammatory state.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18029454      PMCID: PMC2243229          DOI: 10.1210/jc.2007-2185

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

1.  Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus.

Authors:  Peter Libby; David M Nathan; Kristin Abraham; John D Brunzell; Judith E Fradkin; Steven M Haffner; Willa Hsueh; Marian Rewers; B Tibor Roberts; Peter J Savage; Sonia Skarlatos; Momtaz Wassef; Cristina Rabadan-Diehl
Journal:  Circulation       Date:  2005-06-28       Impact factor: 29.690

2.  Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation.

Authors:  C G Schalkwijk; D C Poland; W van Dijk; A Kok; J J Emeis; A M Dräger; A Doni; V W van Hinsbergh; C D Stehouwer
Journal:  Diabetologia       Date:  1999-03       Impact factor: 10.122

3.  High-sensitivity C-reactive protein and impaired coronary vasoreactivity in young men with uncomplicated type 1 diabetes.

Authors:  J Sundell; T Rönnemaa; H Laine; O T Raitakari; M Luotolahti; P Nuutila; J Knuuti
Journal:  Diabetologia       Date:  2004-11-24       Impact factor: 10.122

4.  Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy.

Authors:  G Targher; L Bertolini; G Zoppini; L Zenari; G Falezza
Journal:  Diabet Med       Date:  2005-08       Impact factor: 4.359

5.  Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility.

Authors:  Yongsoo Park; Sukyung Park; Eunkyung Yoo; Dukhee Kim; Hyongdoo Shin
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

6.  Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study.

Authors:  M T Schram; N Chaturvedi; C G Schalkwijk; J H Fuller; C D A Stehouwer
Journal:  Diabetologia       Date:  2005-02-04       Impact factor: 10.122

7.  Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E.

Authors:  Kathrin S Michelsen; Michelle H Wong; Prediman K Shah; Wenxuan Zhang; Juliana Yano; Terence M Doherty; Shizuo Akira; Tripathi B Rajavashisth; Moshe Arditi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

8.  Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes.

Authors:  Rieko Hayaishi-Okano; Yoshimitsu Yamasaki; Naoto Katakami; Kentaro Ohtoshi; Shin-Ichi Gorogawa; Akio Kuroda; Munehide Matsuhisa; Keisuke Kosugi; Norikiyo Nishikawa; Yoshitaka Kajimoto; Masatsugu Hori
Journal:  Diabetes Care       Date:  2002-08       Impact factor: 19.112

9.  C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification.

Authors:  Helen M Colhoun; Casper Schalkwijk; Michael B Rubens; Coen D A Stehouwer
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112

10.  Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways.

Authors:  Harry Björkbacka; Vidya V Kunjathoor; Kathryn J Moore; Stephanie Koehn; Christine M Ordija; Melinda A Lee; Terry Means; Kristen Halmen; Andrew D Luster; Douglas T Golenbock; Mason W Freeman
Journal:  Nat Med       Date:  2004-03-14       Impact factor: 53.440

View more
  147 in total

1.  Altered Toll-like receptor signaling pathways in human type 1 diabetes.

Authors:  Adam J Meyers; Roopali R Shah; Peter A Gottlieb; Danny Zipris
Journal:  J Mol Med (Berl)       Date:  2010-08-20       Impact factor: 4.599

2.  Calcitriol plays a protective role in diabetic nephropathy through anti-inflammatory effects.

Authors:  Li Mao; Feng Ji; Yuanyuan Liu; Wei Zhang; Xianghua Ma
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  The Role of Toll-Like Receptors in Diabetes-Induced Inflammation: Implications for Vascular Complications.

Authors:  Ishwarlal Jialal; Harmeet Kaur
Journal:  Curr Diab Rep       Date:  2012-02-08       Impact factor: 4.810

4.  Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data.

Authors:  Theodore Mazzone
Journal:  Circulation       Date:  2010-11-23       Impact factor: 29.690

Review 5.  Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.

Authors:  Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman
Journal:  Endocr Rev       Date:  2008-07-29       Impact factor: 19.871

6.  Icariin prevents cytokine-induced β-cell death by inhibiting NF-κB signaling.

Authors:  Shao Zhong; Jing Ge; Jiang-Yi Yu
Journal:  Exp Ther Med       Date:  2018-07-20       Impact factor: 2.447

Review 7.  Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates.

Authors:  Paul Chamberlain; Bonita Rup
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

Review 8.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

9.  Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy.

Authors:  Jin Ma; Huiling Wu; Cathy Y Zhao; Usha Panchapakesan; Carol Pollock; Steven J Chadban
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

10.  Increased secretion of IP-10 from monocytes under hyperglycemia is via the TLR2 and TLR4 pathway.

Authors:  Sridevi Devaraj; Ishwarlal Jialal
Journal:  Cytokine       Date:  2009-05-15       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.